SA 55
Alternative Names: BD55-5514; SA-55Latest Information Update: 28 Feb 2026
At a glance
- Originator Sinovac Biotech
- Class Antibodies; Antivirals
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID 2019 infections
Most Recent Events
- 28 Feb 2026 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections(In adolescents, In children, In the elderly, In infants, In adults) in China (IM, Injection)
- 28 Feb 2026 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections(In adolescents, In children, In the elderly, In infants, Prevention, In adults) in China (IM, Injection)
- 15 Oct 2025 No development reported - Phase-I for COVID-2019 infections (In the elderly, Prevention, In adults) in China (Inhalation)